Objective: This study aimed to evaluate the usefulness of recursive partitioning analysis model established by the Radiation Therapy Oncology Group for predicting the survival of patients with supratentorial glioblastoma treated with radiotherapy and to determine prognostic factors for the subgroups of this prognostic model. Methods: A total of 108 glioblastoma patients treated with radiotherapy between January 1987 and December 2005 were retrospectively reviewed. Recursive partitioning analysis classes III, IV, V and VI included 8, 29, 32 and 39 patients, respectively. These classes were divided into two subgroups: a good prognostic group containing classes III -IV and a poor prognostic group containing classes V -VI. The median radiation dose was 60 Gy. Seventyfive patients received chemotherapy and/or immunotherapy. Results: The overall survival differed significantly among classes III, IV, V and VI, with median survival times of 34, 15, 11 and 7 months, respectively. Among the good prognostic group, patients with basal ganglia invasion showed poorer survival outcomes than patients without basal ganglia invasion. Among the poor prognostic group, patients with tumor sizes of ,5 cm and patients treated with nimustine hydrochloride showed better survival outcomes than those with tumor sizes of !5 cm and those without treatment with nimustine hydrochloride, respectively. Conclusions: This study confirms the prognostic value of the recursive partitioning analysis grouping. Basal ganglia invasion could be a useful predictive factor for survival in the good prognostic group, whereas tumor size and treatment with nimustine hydrochloride could be useful predictive factors in the poor prognostic group.
INTRODUCTION
Supratentorial glioblastoma (GB) is the most frequent primary brain tumor in adults. Despite multimodality treatments involving surgery followed by adjuvant radiotherapy (RT) and chemotherapy, the prognosis of GB patients remains poor, with a median survival time (MST) of ,1 year. Some authors (1 -3) have reported that patientdependent prognostic factors are important for predicting the survival outcome. The most significant prognostic factor in GB is age, followed by Karnofsky performance status (KPS) and mental status (1) . The use of standardized criteria to assign GB patients to prognostic groups allows meaningful comparisons of treatment results and provides a system that can be used to determine the type of treatment for individual patients. Curran et al. (1) previously reported recursive partitioning analysis (RPA) classes based on the results of three randomized Radiation Therapy Oncology Group (RTOG) trials. Concerning GB patients, four prognostic classes that differed significantly in their survival rates were identified. Several retrospective studies (4 -7) have demonstrated that the RPA model developed by the RTOG is valid for determining the prognosis of GB patients treated with RT. However, a portion of patients with RPA classes III -IV have relatively poor prognoses. On the other hand, a portion of patients with RPA classes V -VI show relatively long-term survival periods. The prognostic factors for these RPA subgroups have not yet been clearly elucidated.
For better understanding of the usefulness of the RTOG-established RPA model, it will be useful to evaluate the RPA grouping of GB patients at a single institution. The aim of this study was to evaluate the use of this RPA model in an attempt to predict the survival rates of GB patients treated with RT, and to further clarify prognostic factors for the RPA subgroups.
PATIENTS AND METHODS

PATIENTS
Between January 1987 and December 2005, a total of 116 patients with a diagnosis of GB underwent RT at Hyogo Cancer Center in Akashi, Japan. Among these patients, five patients were excluded from this study because four were aged ,18 years and one had concurrent lung cancer at the time of diagnosis. An additional three patients who received temozolomide (TMZ) at recurrence were excluded because the addition of TMZ may provide a significant survival benefit. The remaining 108 patients were identified and retrospectively analyzed. The characteristics of the patients and their tumors are summarized in Table 1 . The patients ranged in age from 21 to 82 years (median, 61 years). Fifty-five patients were male and 53 patients were female. The KPS of the patients ranged from 20 to 100% (median, 70%). All the tumors were histologically diagnosed as supratentorial GB. The preoperative tumor size ranged from 20 to 100 mm (median, 50 mm). Nine patients had multifocal disease. Basal ganglia invasion (BGI) on radiological estimation was observed in 19 (18%) patients.
PROGNOSTIC GROUPS
The patients were staged according to the RPA model proposed by Curran et al. (1) . The descriptions of the prognostic factors for defining each class are detailed in Table 2 .
Patients eligible for their model were aged between 18 and 70 years with KPS scores of .40. To also evaluate the treatment outcomes of patients aged .70 years and those with KPS scores of ,40, all the patients in the present study were included and assigned to RPA classes according to the model. RPA classes III, IV, V and VI included 8 (7%), 29 (27%), 32 (30%) and 39 (36%) patients, respectively. Jpn J Clin Oncol 2010;40(8) 727
TREATMENTS
The treatments given to the patients are summarized in Table 3 . All the patients underwent an initial surgical intervention: 4 (4%) had a complete resection, 27 (25%) had a subtotal resection, 54 (50%) had a partial resection and 23 (21%) had a biopsy only. Surgery was confined to biopsy or partial resection in 17 of 19 (90%) patients with BGI. After the surgical treatment, all the patients received RT. The time from surgical resection to RT ranged from 0.2 to 4.6 months (median, 0.8 months). Fifty-seven (53%) patients underwent RT within 1.5 months of the day of surgery. RT was delivered by 4-and/or 10-MV photons from linear accelerators. Immobilization was achieved using a thermoplastic mask. Daily fractions of 1.8 -2.0 Gy for 5 days per week were most frequently used. Thirty-four patients were treated with accelerated hyperfractionated RT using two fractions per day of 1.5 -1.8 Gy to a total dose of 12.8 -68.4 Gy (median, 60.8 Gy). The total dose to the primary site in all 108 patients ranged from 12.8 to 70.2 Gy (median, 60 Gy). Computed tomography (CT)-guided treatment planning was performed in 57 patients. The treatment volume was based on preoperative CT and/or gadolinium-enhanced magnetic resonance imaging (MRI) of the brain. The initial target volume generally included the contrast-enhanced lesion and surrounding edema plus a 2-to 3-cm margin for the first 45 -50.4 Gy. Thereafter, the target volume included the enhanced lesion only plus a 2-to 3-cm margin. The treatment was planned using an isocentric technique with multiple coplanar or non-coplanar beams. Nine patients with a bulky tumor or poor KPS received RT on a whole brain field. Overall, 97 of the 108 patients completed the irradiation treatment as planned. Among the remaining 11 patients, the treatment was interrupted in nine patients owing to worsening of the KPS and two patients because of their refusal to continue. The total dose in these nine patients ranged from 12.8 to 52 Gy (median, 30 Gy).
Seventy-five (69%) patients received various regimens and doses of chemotherapy and/or immunotherapy before, during and/or after RT. A combination of nimustine hydrochloride (ACNU) and interferon (IFN)-b was the most common regimen and was delivered to 54 patients. The other regimens consisted of ACNU, IFN-b, picibanil and/or human monoclonal antibody CLN-igG. CLN-igG was produced by fusing UC729-6, a human lymphoblastoid B-cell line, with lymphocytes obtained from a patient with adenocarcinoma of the cervix (17) . Phase I -II clinical trials of CLN-igG for malignant glioma were carried out cooperatively by Japanese institutions. Overall, 14 of 108 (13%) GB patients treated at our institution were enrolled in these trials. At progression, patients were considered for reoperation, stereotactic radiosurgery and/or chemotherapy/immunotherapy including various drug combinations based on ACNU, cisplatin, carboplatin, etoposide, procarbazine, lomustine, vincristine, methotrexate, ifosfamide, cytarabine, IFN-b or CLN-igG.
STATISTICAL ANALYSIS
The overall survival (OS) was calculated from the first day of irradiation until the most recent follow-up or death. The survival rates were calculated using the Kaplan -Meier method and comparisons of the survival rates were carried out using the log-rank test. Multivariate analyses were performed using the Cox proportional hazard model to define the independent contributions of individual prognostic factors. For all tests, a value of P , 0.05 was considered to indicate statistical significance.
RESULTS
After a median follow-up of 11 months (range, 1 -51 months), 102 patients had died from GB and three had died of other diseases (malignant lymphoma in one, heart failure in one and sudden death in one). Three patients were alive at the last follow-up, but one of these had a recurrence of GB.
The OS curves for all 108 patients are shown in Fig. 1 . The survival periods after the start of RT for all the GB patients ranged from 0.9 to 50.8 months (median, 11.1 months). The 1-, 2-and 4-year OS rates for all the patients were 45, 19 and 2%, respectively. Twenty of the 108 patients showed long-term survival periods of longer than 2 years. The median OS periods for RPA classes III, IV, V and VI were 36, 16, 10 and 7 months, respectively, with 2-year survival rates of 75, 30, 16 and 3%, respectively (P , 0.01, Fig. 2) . 
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RPA grouping of GB patients
Next, the patients were stratified into two subgroups based on the RPA classes: a good prognostic (GP) group containing RPA classes III -IV and a poor prognostic (PP) group containing RPA classes V -VI. These groups were analyzed separately for the OS rates and predictive factors for OS. The MSTs for the patients in the GP and PP groups were 21 and 9 months, respectively (P , 0.01, Fig. 3) . The results for univariate analyses of the characteristics of the patients and treatments regarding OS are shown in Table 4 . In the GP group, patients with BGI showed a worse prognosis than patients without BGI (MSTs of 7 and 23 months, respectively, P , 0.01). In the PP group, patients with preoperative tumors measuring ,5 cm and patients who received chemotherapy involving ACNU showed better OS rates than the remaining patients (MSTs of 11 months for tumor size of ,5 cm versus 7 months for tumor size of !5 cm and MSTs of 12 months for ACNU treatment versus 8 months for no ACNU treatment). However, there were no significant differences between the survival rates with respect to sex, interval period from surgery to the start of irradiation, method of RT or treatment with IFN-b. To determine independent prognostic factors, BGI, tumor size and ACNU treatment were entered into multivariate analyses. The results are summarized in Table 5 . In the multivariate analyses, BGI [hazard ratio (HR), 8.29; P , 0.01] was associated with a worse OS in the GP group. On the other hand, tumor size of ,5 cm (HR, 0.52; P , 0.01) and ACNU treatment (HR, 0.47; P , 0.01) were associated with an improved OS in the PG group. 
DISCUSSION
RPA classes were previously published for a dataset of 1578 patients with malignant gliomas entered into three RTOG randomized clinical trials (1). Thereafter, several authors (4 -7) have indicated that the RPA model developed by the RTOG is a useful tool for determining the prognosis of GB patients treated with RT. In the RTOG studies, however, patients above 70 years of age and patients with KPS scores of ,40 were excluded. Marijnen et al. (6) reported that including patients above 70 years of age in the RPA groups did not lead to worse survival compared with the RTOG results. It has also been suggested that the RTOG RPA model is even functional in a single institution, when GB patients above 70 years of age are included. Therefore, we evaluated the prognostic impact of the RTOG RPA scores for all GB patients treated with RT at our institution. As a result, MSTs of 36, 16, 10 and 7 months were obtained for RPA classes III, IV, V and VI, respectively, with significant differences. For the RTOG patients, these figures were 17.9, 11.1, 8.9 and 4.6 months, respectively. Although comparisons among studies have to be approached with caution, our present results appear promising and support those reported by Marijnen et al. (6) . These findings suggest that the RTOG RPA model could be a useful tool for evaluating the prognosis of GB patients, regardless of patient age and KPS. Nevertheless, a portion of patients in the GP group had relatively poor prognoses. On the other hand, a portion of patients in the PP group showed relatively long-term survival periods. In the GP group, BGI was found to be a prognostic predictor for poor survival. Although the reason behind this finding remains unclear, difficulty in complete removal of a tumor with BGI may be one of the possible reasons. Talos et al. (8) assessed the main variables that affect complete MRI-guided resection of a supratentorial low-grade glioma. In their univariate analyses, 11 variables containing BGI were found to be associated with incomplete resection. In our study, the majority of patients (90%) with BGI underwent surgery confined to biopsy only or partial resection. Although the issue of whether the extent of resection is a factor that is significantly associated with a survival advantage is much debated, this important question remains unanswered. Several authors (9 -11,16) have suggested that the extent of surgical resection could be a prognostic factor for survival in GB patients treated with RT. For example, Simpson et al. (9) reported the influence of the extent of surgery on the survival of GB patients treated in three RTOG trials employing surgery and irradiation plus or minus chemotherapy. In their report, the MSTs of patients who were treated by total resection, partial resection and biopsy only were 11.3, 10.4 and 6.6 months, respectively, and these values differed significantly. Stummer et al. (11) also reported that patients with complete resection survived for a significantly longer period than those with incomplete resection (16.7 versus 11.8 months). Moreover, their multivariate analyses demonstrated a significant independent prognostic impact of complete resection on survival. On the basis of the above results, tumor involvement of deep and functionally critical structures such as the basal ganglia may lead to a poor prognosis, even in the GP group.
In an RTOG study, Curran et al. (1) analyzed the associations among survival and pretreatment characteristics, as well as treatment-related variables of irradiated patients with a malignant glioma. As a result, tumor size (!5 versus ,5 cm) was not a relevant prognostic factor for survival. However, tumor size (!5 versus ,5 cm) was found to be a significant predictor of OS for patients in the PP group in the present study. Shikama et al. (4) reported similar results for RT (60 Gy) for GB patients in RPA classes V -VI. In their report, the MST of patients with a tumor size of ,5 cm was 14 months and significantly longer than the MST of 9 months for patients with a tumor size of !5 cm. Furthermore, Talos et al. (8) revealed that a large tumor volume is a significant predictive variable for incomplete resection. As mentioned above, patients with complete tumor resection have the possibility to achieve longer survival. These results suggest that careful and aggressive treatment should be applied for patients with small tumors, even in the PP group.
A recent phase III clinical trial conducted by the European Organization for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) (12) demonstrated that addition of TMZ to RT provides a significant and clinically meaningful survival benefit. On the basis of these results, TMZ was implemented as part of the standard treatment for newly diagnosed GB. In 2006, we also initiated the use of TMZ in the treatment of GB. However, it is not clear whether the advantage of the combined treatment of RT/TMZ remains beneficial in all RPA classes. Mirimanoff et al. (7) used RPA methodology to evaluate the effect of combined TMZ/RT in RPA classes III -V of the EORTC/NCIC randomized study. In that study, the survival of patients with RPA class III was significantly higher for combined TMZ/RT (MST of 21 months and 2-year survival rate of 43%) than for RT alone (MST of 15 months and 2-year survival rate of 20%). For RPA class IV patients, the survival advantage remained significant, with MSTs of 16 versus 13 months, respectively, and 2-year survival rates of 28 versus 11%, respectively. For RPA class V patients, however, the survival advantage of RT/TMZ was of borderline significance. Consequently, the advantage of the combined treatment of RT/TMZ remains unclear for RPA classes V -VI. In the present study, use of ACNU for RPA classes V -VI was found to be an independent prognostic factor for OS. Adjuvant treatment with nitrosoureas has been justified by trials showing a small long-term survival benefit in patients with malignant glioma treated with surgery followed by nitrosoureas plus RT compared with surgery followed by RT alone (13 -15) . However, no conclusive comparisons between nitrosoureas and TMZ have been published. A prospective trial to investigate the optimal treatments for each prognostic group is warranted.
In conclusion, the present study confirms the prognostic value of the RTOG RPA grouping for GB patients treated with RT, irrespective of patient age and KPS. Multivariate analyses for prognostic factors demonstrated that BGI could be a significant prognostic factor affecting OS in the GP group, although tumor size and ACNU treatment could be significant prognostic factor affecting OS in the PP group. Our findings may help to refine the clinician's prediction and treatment decisions. However, this was a single institution retrospective study comprising a relatively small number of patients, and further evidence should be accumulated based on prospective trials to determine the prognostic factors and individualize the treatment strategies for patients with GB.
